PB Healthcare Buys Fitterfly to Expand into Preventive Digital Care

PB Healthcare Services Ltd, a subsidiary of PB Fintech, announced the acquisition of digital health platform Fitterfly as part of its strategy to move beyond hospital-based care and strengthen its preventive healthcare offerings. 

The acquisition reflects PB Health’s broader mission to create a connected and tech-driven healthcare ecosystem integrating hospitals, doctors, insurers, and patients.

Building a Prevention-First Healthcare Ecosystem

PB Health is currently developing a 1,200-bed hospital network in Delhi NCR, including a 270-bed hospital in Noida and two additional facilities in Gurgaon. The company aims to promote a cashless, connected, and prevention-first healthcare model that bridges the trust gap between hospitals and insurers.

Through the acquisition, PB Health will integrate Fitterfly’s digital expertise in diabetes reversal, obesity management, and heart health into its platform. This move expands PB Health’s presence in out-of-hospital and preventive care, aligning with its long-term goal of reducing avoidable hospitalisations.

AI Integration and Technology-Led Transformation

PB Health is embedding Artificial Intelligence (AI) across its operations to drive efficiency and improve outcomes. Its AI-enabled systems include voice-to-text clinical documentation, smart reporting, and AI-assisted decision support for doctors.

“Our vision is to create a truly integrated healthcare ecosystem where patients experience frictionless, high-quality care,” said Yashish Dahiya, Chairman and Group CEO of PB Fintech, as per the news reports. “We are building a tech-first healthcare platform that improves outcomes, enhances trust, and redefines the care journey for millions across India.”

Fitterfly’s Role in PB Health’s Preventive Strategy

Founded by Dr Arbinder Singal and known for its clinically validated digital programmes, Fitterfly focuses on managing chronic diseases such as diabetes, hypertension, dyslipidemia, and obesity, conditions affecting up to 40% of Indian adults.

“Our platform, with its proven outcomes and intellectual property, will add significant value to PB Health’s integrated ecosystem,” said Dr Singal, CEO of Fitterfly. The acquisition is expected to strengthen PB Health’s chronic disease management capabilities and accelerate its preventive healthcare strategy.

Read More: Metropolis Healthcare Q2 Profit Up 13% Driven by TruHealth and Specialty Tests!

Leadership Expansion and Strategic Funding

In addition to the acquisition, PB Health announced key leadership appointments to strengthen its management team:

• Rajeev Bhandari – Formerly with Evercare and Fortis Hospitals
• Dr Mohit Mathur – Formerly with Max Hospitals
• Air Marshal Dr Rajesh Vaidya – Former DG Medical Services, Indian Air Force

The company also highlighted its recent $218 million fundraise in May 2025 from General Catalyst, Faering Capital, Bay Capital, Think Investments, Avataar, and Select Group — one of India’s largest early-stage healthcare funding rounds. The capital will fuel PB Health’s expansion into preventive, AI-enabled healthcare solutions.

PB Fintech Share Price Performance

On November 6, 2025, PB Fintech share price opened at ₹1,810.20 on NSE, below the previous close of ₹1,823.10. During the day, it surged to ₹1,812.50 and dipped to ₹1,750.00. The stock is trading at ₹1,753.70 as of 1:09 PM. The stock registered a significant decline of 3.81%.

Over the past week, it has declined by 4.92%, over the past month, it has declined by 0.64%, and over the past 3 months, it has moved up by 1.05%.

Conclusion

PB Healthcare’s acquisition of Fitterfly marks a strategic leap toward creating an integrated, tech-first, and prevention-oriented healthcare ecosystem in India. Combining AI-driven hospital operations with digital chronic care management, PB Health is positioning itself at the forefront of the country’s evolving healthcare transformation.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in securities are subject to market risks. Read all related documents carefully before investing.